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SR-BI is a cell surface HDL receptor that mediates selective uptake of the lipid cargo of HDL, an important process in hepatocytes,
driving reverse cholesterol transport from cells in the artery wall. To facilitate examination of factors that modulate SR-BI activity
in hepatocytes, we have generated ﬂuorescent protein-tagged versions of SR-BI that allow for facile monitoring of SR-BI protein
levels and distribution in transfected cells. We show that deletion of the C-terminal cytosolic tail does not aﬀect the distribution of
SR-BI in HepG2 cells, nor is the C-terminal cytosolic tail required for SR-BI-mediated uptake of HDL lipids. We also demonstrate
that the phorbol ester, PMA, increased, while protein kinase C inhibitors reduced SR-BI-mediated HDL lipid uptake in HepG2
cells. These data suggest that protein kinase C may modulate selective uptake of HDL lipids including cholesterol in hepatocytes,
thereby inﬂuencing hepatic HDL cholesterol clearance and reverse cholesterol transport.
1.Introduction
High-densitylipoproteins(HDL)mediatereversecholesterol
transport from cells in the artery wall to the liver where
cholesterolandcholesterylesteraretakenupbythescavenger
receptor class B type 1 via a process known as selective
lipid uptake [1]. This is the uptake of the lipid components
of the HDL particle without the net internalization and
degradation of the particle itself [2]. Reverse cholesterol
transport (RCT) driven by SR-BI in the liver, therefore,
represents a key pathway for hepatic clearance of HDL
cholesterol and prevention of the build-up of cholesterol
in inﬂammatory cells in the artery wall, thereby protecting
against atherosclerosis [3, 4]. Studies from gene-targeted
mouse models have demonstrated that knocking out SR-
BI expression results in impaired hepatic clearance of HDL
cholesterol leading to increased amounts of cholesterol in
the blood associated with abnormally large HDL particles,
as well as reduced levels of cholesterol in bile [5–11]. On
the other hand, overexpression of SR-BI in livers of mice
results in increased clearance of HDL cholesterol and is
accompanied by reduced levels of cholesterol associated with
HDL in blood, and increased levels of cholesterol in bile [12–
14].
Epidemiological studies have revealed that higher levels
of HDL cholesterol in blood are associated with protection
and that lower levels of HDL cholesterol in blood are
associated with increased risk for atherosclerosis leading to
heartdisease[15].Inlightofthis,theﬁndingthateliminating
SR-BI expression increases while its overexpression reduces
atherosclerosis in mice [6, 8, 16–19] may appear surprising.
The results can be reconciled by considering the activity of
RCT as the important atheroprotective factor rather than
the absolute level of HDL cholesterol in the blood. Thus,
knocking out SR-BI expression in mice results in impaired
RCT due to a lack of expression of SR-BI in livers [20]. This
leads to the appearance of unusually large, cholesterol laden
HDL particles because cholesterol cannot be cleared from
HDL by selective uptake. This accumulation of cholesterol
in HDL, in turn, reduces the ability of HDL to remove
excess cholesterol from the artery wall, thereby increasing
the development of atherosclerosis. On the other hand,
overexpressing SR-BI in livers of mice results in increased2 Cholesterol
RCT activity, characterized by an increase in the clearance of
HDL cholesterol from blood, and leads to reduced steady-
state blood HDL cholesterol levels. The increased RCT
activity also increases clearance of cholesterol by HDL from
cells in the artery wall, resulting in reduced development
of atherosclerosis. This has been supported by studies that
demonstrate the eﬀects of manipulating SR-BI expression
on HDL cholesterol clearance, steady-state levels of HDL
cholesterol in blood and cholesterol in bile, and on the
development of atherosclerosis in mouse model systems
[5–14, 16–20]. Understanding factors that regulate SR-BI
activity will therefore shed light on pathways that may
regulate RCT activity in vivo.
SR-BI is a 509 amino acid protein that is heavily
glycosylated and embedded in the plasma membrane via
two transmembrane domains, close to the N- and C-termini
of the protein [4]. SR-BI contains two cytosolic regions,
one of approximately 10 amino acids at its N-terminus
and the other of ∼40 amino acids at its C-terminus [4].
The terminal 3-4 amino acids of the C-terminal cytosolic
domain represents a binding site for an adaptor protein
called PDZK1 which plays an important role in protecting
SR-BI protein from degradation in hepatocytes [21–23]. The
precise sequences that direct SR-BI towards degradation in
the absence of PDZK1 binding remain to be identiﬁed;
however it is presumed that they reside in the C-terminal
cytosolic tail of SR-BI. PDZK1 may thus represent one
mechanism by which SR-BI protein levels can be adjusted
to regulate RCT activity. Indeed PDZK1 has been shown to
be phosphorylated by protein kinase A, which appeared to
be necessary for its ability to stabilize SR-BI [24]. PDZK1’s
role in stabilizing SR-BI, however, is tissue speciﬁc since
elimination of PDZK1 in mice results in the virtual absence
of SR-BI protein in hepatocytes, only partially reduced levels
in intestinal cells, and no observed eﬀects on other tissues
[25, 26].
We have previously reported that the protein kinase C
(PKC) activators, phorbol esters, can increase, while speciﬁc
PKC inhibitors can reduce SR-BI-dependent lipid uptake
in transfected Chinese hamster ovary cells overexpressing
SR-BI [27]. This was accompanied by opposite eﬀects on
the level of cell association of the HDL particles themselves
indicating that PMA activates and PKC inhibitors reduce
SR-BI-dependent selective lipid uptake activity. The role of
PKC activity on SR-BI-mediated lipid uptake in hepatocytes,
however, is not known. Here we demonstrate that SR-BI
overexpression in HepG2 cells mediates increased cellular
HDL lipid uptake. Using this system, we demonstrate that
PMA enhances and PKC inhibitors suppress SR-BI-mediated
HDL lipid uptake in hepatocytes. This sensitivity to PKC
inhibitors is not aﬀected by the removal of the cytosolic C-
terminus of SR-BI, nor does it involve alterations in the level
of SR-BI expression or distribution.
2.MaterialsandMethods
2.1. Cell Culture and Transfection. Expression plasmids for
full-length human SR-BI and SR-BI-ΔC (lacking the C-
terminal cytosolic tail) fused at their N-termini to either
enhanced green ﬂuorescent protein (eGFP) or momeric red
ﬂuorescent protein (mRFP) have been described previously
[28]. For transfection, HepG2 cells were seeded at a density
of 5 × 105 cells per well in 6-well dishes and cultured in
Dulbecco’s modiﬁed eagle’s medium containing 5% fetal
bovine serum, 2mM L-glutamine and penicillin (50U/ml)
and streptomycin (50 μg/ml). On the following day, 3μL
of Fugene 6 transfection reagent and 97μL of serum-free
medium were mixed and incubated at RT for 5min prior
to the addition of 1μg of plasmid DNA and further gentle
mixing. After incubation for a further 20min, the mixture
was added to one well containing 2mL of fresh growth
medium. The dishes were rocked back and forth and side
to side to ensure even distribution of the transfection
solution. The cells were cultured for 48hrs prior to use for
experiments.
To select for stably expressing cells, the transfected
HepG2 cells were cultured in growth medium containing
500μg/mL of G418 beginning 24hrs after transfection.
After 4 days, cells selected with G418 were further sorted
individually into wells of a 96-well plate in order to isolate
clonalcelllines.Sortedcellswereculturedingrowthmedium
containing 500μg/mL of G418. The medium was replaced
with fresh medium every 2 days. Once the cells could be seen
in each well, eGFP expression was analyzed by ﬂuorescence
wide-ﬁeld microscopy using an Axiovert 200M inverted
ﬂuorescence microscope (Carl Zeiss Canada Inc). Isolates
expressing eGFP were expanded, and expression eGFP and
SR-BI was characterized by immunoblotting.
2.2. Fluorescence Microscopy. Cells cultured on poly-D-
lysine coated, glass-bottomed dishes were ﬁxed with freshly
prepared 2.5% paraformaldehyde in phosphate-buﬀered
saline (PBS). Cells were incubated for 4min in 2mL of
300nM 4 -6-diamidino-2-phenylindole (DAPI) in PBS to
stain nuclei. Stained cells were washed 3 times with PBS, and
ﬂuorescence microscopy was performed using an Axiovert
200M inverted ﬂuorescence microscope (Carl Zeiss Canada
Inc). Fluorescence images were captured with Zeiss ﬁlter sets
Fs01 (excitation: band pass 365/12 and emission: long pass
397; DAPI imaging), Fs13 (excitation: band pass 470/20 and
emission: band pass 505–530; eGFP imaging), and/or Fs15
(excitation: band pass 546/12 and emission: long pass 590;
mRFP imaging).
2.3. SDS-PAGE and Immunoblotting. Cell lysates were pre-
pared as previously described [27], and protein concentra-
tions were determined using the BCA Protein Assay Kit
(Pierce). Protein electrophoresis under denaturing condi-
tions and immunoblotting were performed as previously
described [28].Cholesterol 3
2.4. DiI-HDL Lipid Uptake Assay. HDL was prepared from
human plasma by KBr ultracentrifugation and labelled with
1,1 -dioctadecyl-3,3,3 ,3 -tetramethylindocarbocyanine per-
chlorate (DiI) as previously described [1, 29, 30]. On day
0, 5 × 105 HepG2 cells were seeded per well of 6-well
dishes. On day 2, the cells were washed once with 1mL of
incompleteDMEM.Forexperimentsrequiringthetreatment
of cells with various inhibitors or activators, the cells were
incubated in incomplete DMEM containing 0.5% BSA and
the inhibitor or activator at the appropriate concentration
for 10min at 37◦C. Following these incubations, DiI-HDL
was added to each well to a ﬁnal concentration of 5μg/mL.
Duplicate wells received 5μg/mL DiI-HDL and a 40-fold
excess (200μg/mL) of unlabeled HDL to allow for the
m e a s u r e m e n to fn o n s p e c i ﬁ cc e l la s s o c i a t i o no fD i Iﬂ u o r e s -
cence. For experiments without treatments with inhibitors
or activators, the DiI-HDL and unlabeled HDL were added
immediately after the wash with incomplete DMEM at the
ﬁnal concentrations stated above. The plates were incubated
at37◦Cfor2hrs.ThecellswerewashedtwicewithcPBS(PBS
containing 0.01% CaCl2 and 0.01% MgCl2) released from
the dishes by trypsinization (0.05% trypsin, 0.53mM EDTA
in PBS) for 2min, washed in ice-cold complete media, and
resuspended in ice-cold PBS containing 0.1% BSA, 0.5mM
EDTA, and 0.1% glucose. The samples were analyzed for DiI
and eGFP ﬂuorescence using a Beckman Coulter Epics XL
ﬂow cytometer. Speciﬁc uptake of DiI from HDL (deﬁned as
the level of uptake that could be competed away by a 40-fold
excess of unlabeled HDL) was determined as the diﬀerence
between the mean DiI ﬂuorescence of the cells incubated
with DiI-HDL alone and the mean DiI ﬂuorescence when
cells were incubated with both DiI-HDL and a 40-fold excess
of unlabeled HDL.
3. Results
We have generated versions of human SR-BI encoding the
full-length polypeptide or a deletion mutant lacking the
40 amino acid C-terminal cytosolic tail (hereafter referred
to as SR-BI-ΔC) and tagged on the N-terminal cytosolic
region with either eGFP- or mRFP [28]( Figure 1). Tagging
with ﬂuorescent proteins allows the facile monitoring of
the levels and distributions of the proteins expressed in
transfected cells, and it allows us to distinguish the full-
lengthandmutantformsoftheproteinindoublytransfected
cells. We have previously demonstrated that tagging of SR-
BI at the N-terminus with ﬂuorescent proteins does not
alter its distribution in cells or its lipid uptake activity
[28]. To examine the involvement of the C-terminal cyto-
plasmic tail of SR-BI in its distribution and activity in
hepatocytes, we transfected plasmids encoding the tagged
wild-type and mutant versions of SR-BI into HepG2 cells
and selected for stably expressing cells by a combination of
drug resistance and ﬂuorescence-activated cell sorting (not
shown). As a control, we also generated HepG2 cells stably
expressing eGFP alone. Figure 2 shows the levels of eGFP-
tagged full-length SR-BI or SR-BI-ΔC, or of eGFP alone
in transfected and stably expressing HepG2[eGFP-SR-BI],
HepG2[eGFP-SR-BI-ΔC], HepG2[eGFP] cells, or untrans-
fected HepG2 cells, as analyzed by SDS-PAGE and detected
by immunoblotting using an antibody against eGFP. No GFP
immunoreactive band was detected in untransfected HepG2
cells as expected. Cells transfected and stably expressing
eGFP alone contained a band migrating between the 26
and 37kDa molecular weight markers, consistent with the
expected 30kDa size of eGFP. Lysates from HepG2[eGFP-
SR-BI] cells contained a band migrating between the 90kDa
and 117kDa molecular weight markers consistent with the
expected size of 115kDa (30kDa eGFP + 85kDa SR-BI).
Lysates from HepG2[eGFP-SR-BI-ΔC] cells contained an
eGFP immunoreactive band that migrated slightly faster
than that in HepG2[eGFP-SR-BI] lysates, consistent with the
expected size of eGFP fused to SR-BI lacking the C-terminal
cytoplasmictail.β-actinwasusedasacontroltodemonstrate
equal loading across all lanes. Interestingly, deletion of the
C-terminal cytosolic tail of SR-BI appeared to correspond
to higher SR-BI protein levels (Figure 2, compare lanes 1
and 2). Results of ﬂow cytometric analysis of HepG2[eGFP-
SR-BI] and HepG2[eGFP-SR-BI-ΔC] cells (see Figure 5(b))
also suggested that truncation of the cytosolic C-terminus
corresponded to higher SR-BI protein levels. We interpret
this to be due to the removal of sequences in the C-terminal
cytosolic tail of SR-BI that are responsible for its degradation
in hepatocytes. It is known that the binding of PDZK1 to the
cytosolic C-terminus of SR-BI is required to stabilize SR-BI
in hepatocytes, since deletion of the PDZK1 binding site (the
last 3 amino acids) from the cytosolic C-terminal tail of SR-
BI or knockout of PDZK1 results in the degradation of SR-BI
[22, 23, 25], presumably due to other sequences present in
the C-terminal cytosolic tail itself.
To examine the eﬀects of deletion of the C-terminal
cytosolic tail of SR-BI on its distribution in HepG2 cells,
we examined HepG2 cells transfected with expression plas-
mids encoding either eGFP-tagged or mRFP-tagged versions
of full-length SR-BI or SR-BI-ΔC( Figure 3). Both eGFP-
tagged or mRFP-tagged full-length SR-BI and SR-BI-ΔC
exhibited similar subcellular distributions in HepG2 cells.
This consisted of punctate staining over the body of cells
with intense staining at regions of the cell periphery,
particularly in areas of cell-cell contact. This corresponds to
the distribution of SR-BI described previously in a variety of
transfected cells or cells expressing endogenous SR-BI [27,
28, 31]. Similar results were seen when we examined stably
expressing HepG2[eGFP-hSR-BI] and HepG2[eGFP-SR-BI-
ΔC] cells (not shown). We also performed immunoﬂuores-
cence microscopy on permeabilized HepG2[mRFP-SR-BI]
cells using an antibody that binds to the C-terminus of SR-
BI, which demonstrated colocalization of the immunoﬂu-
orescence and the mRFP signals (data not shown). This
conﬁrmed that the ﬂuorescent protein signals represented
the distribution of the intact tagged SR-BI.
To conﬁrm that the deletion of the C-terminal cytosolic
tail of SR-BI did not alter its distribution in HepG2 cells,
we transfected HepG2 cells with both eGFP-SR-BI and
mRFP-SR-BIΔC expression plasmids (Figures 4(a)–4(d)).
This allowed us to examine the distribution of full-length
SR-BI and SR-BI-ΔC in the same cells, by examining the4 Cholesterol
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Figure 1: Diagrams of the eGFP or mRPF-tagged SR-BI and SR-
BI-ΔC transgenes. The constructs consist of either SR-BI or SR-
BI-ΔC tagged with either eGFP or mRFP on their amino termini.
The locations of putative transmembrane domains (TMDs) are
also shown. Cytosolic regions are shown in yellow and extracellular
regions are shown in blue.
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Figure 2: Expression of eGFP-SR-BI or eGFP-SR-BI-ΔCi nH e p G 2
cell lines. Cell lysates prepared from HepG2[eGFP-SR-BI] (lane 1),
HepG2[eGFP-SR-BI-ΔC] (lane 2), HepG2 (untransfected) (lane 3),
and HepG2[eGFP] cells (lane 4) were subjected to SDS-PAGE and
immunoblotting for eGFP (upper panel) or β-actin (lower panel).
distribution of the green and red ﬂuorescent protein tags.
Figures 4(b) and 4(c) demonstrate the similarity in the dis-
tribution of eGFP-SR-BI and mRFP-SR-BI-ΔC in the same
cells. The merged image shown in Figure 4(d) demonstrates
substantial colocalization of the green and red ﬂuorescent
proteinsignals,particularlyatthecellperipheryintheregion
of cell-cell contact. To conﬁrm that the distributions of
full length SR-BI or SR-BI-ΔC were not inﬂuenced by the
ﬂuorescent protein tag, we reversed the ﬂorescent protein
tags by examining HepG2 cells cotransfected with plasmids
encoding eGFP-SR-BI-ΔC and mRFP-SR-BI and observed
similar results (Figures 4(e)–4(h)).
We tested the eﬀects of deletion of the C-terminal
cytosolic tail of SR-BI on its ability to mediate the uptake
of lipids from HDL in HepG2 cells. Untransfected HepG2
cells or stably expressing HepG2[eGFP-SR-BI] cells or
HepG2[eGFP-SR-BI-ΔC] cells were incubated with 100
μg/ml HDL containing the ﬂuorescent exchangeable lipid
DiI for 2 hours at 37◦C. Cells were then examined by ﬂow
cytometry for DiI ﬂuorescence and for eGFP ﬂuorescence
(as a measure of the abundance of tagged SR-BI protein).
Previous research from a number of labs has demonstrated
that, despite the diﬀerences in the structures of DiI and
cholesterol, DiI uptake from HDL is an eﬀective surrogate
for the uptake of HDL lipids including cholesterol [1].
Untransfected HepG2 cells exhibited very low DiI-HDL lipid
uptake activity that was close to background (Figure 5(a)).
In contrast, HepG2 cells stably expressing either eGFP-SR-
BIoreGFP-SR-BI-ΔCexhibitedsubstantiallyincreasedlevels
of DiI uptake from HDL, demonstrating that overexpression
of either full-length SR-BI or SR-BI-ΔC confers increased
HDL lipid uptake (Figure 5(a)). We noted signiﬁcantly
higher levels of DiI uptake in HepG2[eGFP-SR-BI-ΔC]
cells than in HepG2[eGFP-SR-BI] cells (Figure 5(a)). This
may be explained by the greater abundance of SR-BI in
HepG2[eGFP-SR-BI-ΔC] cells than in HepG2[eGFP-SR-BI]
cells as revealed by ﬂow cytometric analysis of eGFP levels
(Figure 5(b)) consistent with the results of immunoblotting
described earlier (Figure 2).
We have previously demonstrated that PMA, a phorbol
ester activator of protein kinase C, increased and that a
protein kinase C inhibitor reduced SR-BI-mediated selective
HDL lipid uptake in transfected Chinese hamster ovary
cells [27]. We therefore tested if activation or inhibition
of protein kinase C aﬀected SR-BI activity in hepato-
cytes overexpressing SR-BI. We treated HepG2[eGFP-SR-
BI], HepG2[eGFP-SR-BI-ΔC], or untransfected HepG2 cells
with PMA, to activate protein kinase C, or with the protein
kinase C inhibitors calphostin C or chelerythrine chloride.
As controls, HepG2 cells overexpressing SR-BI or SR-BI-
ΔC were treated with the small molecule SR-BI inhibitor
BLT-1, which is known to inhibit SR-BI dependent HDL
lipid uptake [32]. After a 10min pre-incubation, cells were
incubated with DiI-HDL in the continued presence of PMA,
and/or the PKC or SR-BI inhibitors for 2 hours at 37◦C
prior to ﬂow cytometric analysis of the level of cell associated
DiI ﬂuorescence (Figure 6). Treatment of HepG2[eGFP-SR-
BI] cells expressing full length SR-BI (Figure 6(a))w i t h
PMA resulted in a statistically signiﬁcant approximately 40%
increase in DiI-HDL lipid uptake. In contrast, treatment
of cells with the protein kinase C inhibitors, chelerythrin
chloride or calphostin C, resulted in an approximately 25%–
40% decreases in DiI-HDL lipid uptake when compared to
control untreated cells. Treatment with the PKC inhibitors
also completely prevented the PMA-mediated increase in
DiI-HDL lipid uptake in HepG2[eGFP-SR-BI] cells. Sim-
ilarly, treatment of cells with BLT-1, the small molecule
inhibitor of SR-BI mediated selective HDL lipid uptake
[33], resulted in a statistically signiﬁcant ∼20% reduction
in HDL lipid uptake and also completely prevented the
PMA mediated increase in HDL lipid uptake. Similar results
were obtained when we tested HepG2[eGFP-SR-BI-ΔC] cells
overexpressing the mutant form of SR-BI lacking the C-
terminal cytosolic tail (Figure 6(b)), although, again, the
level of HDL lipid uptake in these cells was greater than
that measured in HepG2[eGFP-SR-BI] cells (compare black
bars in panels (a) and (b)). In fact, PMA treatment didCholesterol 5
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Figure 3: Localization of ﬂuorescent protein-tagged SR-BI containing or lacking the C-terminal tail in transfected HepG2 cells. HepG2 cells
transfected with eGFP-SR-BI ((a)–(c)), eGFP-SR-BI-ΔC ((d)–(f)), mRFP-SR-BI ((g)–(i)), or mRFP-SR-BI-ΔC ((j)–(l)) were ﬁxed, stained
with DAPI and imaged by wide ﬁeld ﬂuorescence microscopy in the blue ((a), (d), (g), and (j)), green ((b) and (e)), or red ((h) and (k))
channels. Merged images of the blue and green ((c) and (f)) or the blue and red ((i) and (l)) channels are also shown. All images are set to
the same scale. Scale bar in (a) = 10μm.
not further increase the high level of HDL lipid uptake
in HepG2[eGFP-SR-BI-ΔC] cells, suggesting it may have
reached a maximum. Nevertheless, treatment with the PKC
inhibitor calphostin C or the SR-BI-speciﬁc inhibitor, BLT-
1, reduced DiI-HDL lipid uptake in HepG2[eGFP-SR-BI-
ΔC] cells (Figure 6(b)). The background level of DiI-HDL
lipid uptake in untransfected HepG2 cells (Figure 6(c))6 Cholesterol
DAPI
(a)
eGFP
(b)
mRFP
(c)
Merged
(d)
(e) (f) (g) (h)
Figure 4: Colocalization of ﬂuorescent protein-tagged SR-BI and SR-BI-ΔC in transfected HepG2 cells. HepG2 cells transfected with both
eGFP-SR-BI and mRFP-SR-BI-ΔC ((a)–(d)) or with both mRPF-SR-BI and eGFP-SR-BI-ΔC ((e)–(h)) expression plasmids were ﬁxed,
stained with DAPI, and imaged by wide-ﬁeld ﬂuorescence microscopy in the blue ((a) and (e)), green ((b) and (f)), and red ((c) and
(g)) channels for DAPI, eGFP, and mRFP, respectively. Merged images are shown in panels (d) and (h). All images are set to the same scale.
Scale bar in (a) = 10μm.
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Figure 5: SR-BI-ΔC retains DiI-HDL lipid uptake activity. HepG2 cells and stably transfected HepG2[eGFP-SR-BI] and HepG2[eGFP-SR-
BI-ΔC] cells were incubated with DiI-HDL and analyzed by ﬂow cytometry for DiI ﬂuorescence (a) or eGFP ﬂuorescence (b). The speciﬁc
uptakeofDiIlipidisshowninpanel(a).ThegeometricmeaneGFPﬂuorescenceforHepG2[eGFP-SR-BI]andHepG2[eGFP-SR-BI-ΔC]cells
is shown in panel (b). The experiment was performed in triplicate, and error bars represent standard deviation.
∗P <. 05 by the Student’s
t-test.
was substantially lower and was not substantially aﬀected
by either PMA or calphostin C treatment (Figure 6(c)).
Therefore, the eﬀects of PMA and calphostin C on HDL
lipid uptake in HepG2[eGFP-SR-BI] and HepG2[eGFP-SR-
BI-ΔC] cells are due to alterations in the activity of the
overexpressed SR-BI. None of the treatments aﬀected the
levels of SR-BI protein as detected by eGFP ﬂuorescence in
HepG2 cells expressing either eGFP-hSR-BI or eGFP-SR-BI-
ΔC (Figures 6(d) and 6(e)). These data indicate that PKC
activity modulates HDL lipid uptake mediated by SR-BI in
hepatocytes.
SR-BI is located on the cell surface as well as intracellu-
larly and continuously cycles between the two compartmentsCholesterol 7
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Figure 6: The protein kinase C inhibitor calphostin C reduces SR-BI-mediated DiI-HDL lipid uptake in HepG2 cells independently of SR-
BI’s C-terminal tail. DiI-HDL lipid uptake (panels (a)-(c)) and eGFP ﬂuorescence (panels (d) and (e)) were measured by ﬂow cytometry.
HepG2[eGFP-SR-BI] cells untreated or treated with 0.5μMP M A ,7 . 5μM chelerythrine chloride, 1μM calphostin C, 300nM BLT-1,
individually or in combination as indicated panels (a) and (d). HepG2[eGFP-SR-BI-ΔC] cells untreated or treated with PMA, calphostin C,
or BLT-1 either individually or in combination as indicated panels (b) and (e). Panel (c): untransfected HepG2 cells treated without or with
PMA or calphostin C individually as above. The data represent average ± standard deviations of triplicate samples.
∗P <. 05 compared to
control by Student’s t-test.
in hepatocytes and a variety of other cell types [27, 28, 34–
38].Activationorinhibitionofphosphatidylinositol3kinase
signaling has been reported to alter the distribution of SR-
BI between the cell surface and internal compartments in
hepatocytes and adipocytes [35, 39]. To determine if the
eﬀects of modulating PKC activity on SR-BI mediated HDL
lipid uptake involved alterations in the distribution of SR-
BI between the cell surface and internal compartments, we
treated HepG2[eGFP-SR-BI] cells with either PMA, the PKC
inhibitor chelerythrin chloride, or vehicle alone and imaged
thecellsbyconfocalﬂuorescencemicroscopy. Neitheractiva-
tion of PKC with PMA nor its inhibition with chelerythrine
chloride resulted in detectable alterations in the subcellular
distribution of eGFP-SR-BI in stably expressing HepG2 cells
when compared to controls that were either untreated (not
shown) or treated with DMSO vehicle alone (Figure 7). This
suggests that neither the activation of PKC nor its inhibition
alters the cell surface localization of SR-BI.8 Cholesterol
Vehicle
(a)
PMA
(b)
Chelerythrine chloride
(c)
Figure 7:ModulatorsofPKCactivitydonotaﬀectSR-BIdistributioninHepG2cells.HepG2[eGFP-SR-BI]cellswereserumstarvedfor4hrs
and then refed medium containing 5% FBS and either vehicle (0.1% DMSO), 0.5 μMP M A ,o r7 . 5μM chelerythrine chloride and incubated
for 1hr. Cells were ﬁxed with 2.5% paraformaldehyde and imaged by confocal microscopy.
4. Discussion
We have utilized an approach in which SR-BI protein levels,
distribution, and activity can easily be monitored in HepG2
cells in order to examine factors that may inﬂuence SR-BI
function in hepatocytes and therefore the activity of RCT.
This approach involves the expression of recombinant forms
of SR-BI containing ﬂuorescent protein tags on their amino
termini. The N-terminus of SR-BI consists of a short 10
amino acid peptide that is predicted to protrude into the
cytosol. Fusion of ﬂuorescent proteins to the N-terminus of
SR-BIdoesnotappeartoalteritsdistributionincells(Figures
3 and 4) or its ability to mediate HDL binding or HDL lipid
uptake (Figure 5)[ 28, 36, 40]. Therefore the use of SR-BI
fused to ﬂuorescent proteins represents a convenient method
to simultaneously monitor eﬀects on SR-BI protein levels,
distribution, and activity.
Using this system, we have demonstrated that the
removal of the cytoplasmic C-terminus of SR-BI does not
prevent it from mediating HDL lipid uptake, indicating that
it is dispensable for this activity in hepatocytes. Similar
ﬁndings have been reported by our group in Chinese
hamster ovary derived cells [28] and by others in MCF-
7 mammary epithelial cells [41]. We did, however, observe
higher protein levels corresponding to the mutant version
of SR-BI lacking the C-terminal cytoplasmic portion (eGFP-
SR-BI-ΔC) compared to the full length SR-BI (eGFP-SR-
BI) in transfected HepG2 cells. This is consistent with
the C-terminal cytoplasmic region of SR-BI directing its
degradation via a pathway that is prevented by PDZK1
binding [21–23, 25]. These ﬁndings suggest that the levels
of full-length SR-BI protein in HepG2 cells overexpressing
eGFP-SR-BI are limited by the availability of PDZK1 and
that any amount of full-length SR-BI in excess of the
available PDZK1 is degraded. On the other hand, eGFP-
SR-BI-ΔC, which lacks the C-terminal cytoplasmic tail and
therefore both the sequences that direct its degradation in
the absence of PDZK1 and the PDZK1 binding site itself,
is not limited by the availability of PDZK1, allowing higher
levels of this protein to accumulate. Consequently, HepG2
cells overexpressing eGFP-SR-BI-ΔC exhibited higher levels
of HDL lipid uptake than did HepG2 cells overexpressing
eGFP-SR-BI (full length) (Figures 5 and 6) due to the higher
SR-BI protein levels.
We have also demonstrated that treatment of HepG2
cells overexpressing eGFP-tagged SR-BI with PKC inhibitors
decreased HDL lipid uptake. Conversely, treatment with
PMA, a phorbol ester that activates PKC, increased HDL
lipid uptake in cells expressing full-length SR-BI. Thus
activation of PKC promotes while PKC inhibitors reduce
SR-BI-mediated HDL lipid uptake in hepatocytes, consistent
with our ﬁndings in transfected Chinese hamster ovary cells.
Deletion of the cytoplasmic C-terminus of SR-BI did not
prevent the ability of PKC inhibitors to suppress SR-BI-
mediated HDL lipid uptake, suggesting that this eﬀect likely
does not reﬂect direct phosphorylation of SR-BI, at least in
its cytosolic C-terminal tail. We also did not observe any
alterations in the abundance of eGFP-tagged SR-BI in cells
treated with either PMA or PKC inhibitors. This, along with
the ﬁnding that the C-terminal cytoplasmic tail of SR-BI was
not necessary, demonstrates that this is likely not through
alterations in the phosphorylation and/or activity of PDZK1.
Finally our results also suggest that activation or inhibition
of PKC does not grossly aﬀect the distribution of SR-BI in
HepG2 cells. Thus, the eﬀect of PKC activity is likely not
through recruitment of SR-BI to the cell surface, as has been
reported to be the consequence of phosphatidyl inositol 3
kinase signaling activity [35, 39].
Recently, Tall and coworkers reported that a novel com-
pound, ITX5061, developed as a p38 mitogen-activated pro-
tein kinase (MAPK) inhibitor, inhibited SR-BI-dependent
HDL lipid uptake in cultured cells overexpressing SR-BI
and that treatment of mice with this compound resulted
in reduced HDL cholesterol clearance from plasma and
increased HDL size and cholesterol content [42]. This
suggeststhatinhibitorsofp38MAPKmayalsoreducehepaticCholesterol 9
SR-BI function and impair RCT. The P38 MAPK pathway
has been shown to be activated by PKC in hepatocytes
and hepatocellular carcinoma cells [43–47]. This raises the
possibility that SR-BI-dependent HDL lipid uptake activity
in hepatocytes is regulated by a pathway involving PKC-
mediated activation of p38 MAPK signaling. However, the
involvement of p38 MAPK signaling in PKC mediated
activation of SR-BI-dependent HDL lipid uptake remains to
be tested. Furthermore the downstream targets of regulation
that mediated the increased SR-BI activity remain to be
identiﬁed. Our studies suggest that regulation of SR-BI-
dependent HDL lipid uptake by PKC does not involve the
C-terminal cytoplasmic tail of SR-BI, the portion of the
molecule that would be the most likely candidate for direct
phosphorylation.
Abbreviations
DAPI: 4 -6-diamidino-2-phenylindole
DiI: 1,1 -dioctadecyl-3,3,3’,3’-
tetramethylindocarbocyanine perchlorate
eGFP: Enhanced green ﬂuorescent protein
HDL: High density lipoprotein
MAPK: Mitogen activated protein kinase
mRFP: Monomeric red ﬂuorescent protein
PBS: Phosphate buﬀered saline
PDZ: Postsynaptic density protein (PSD-95)/
Drosophila disc large tumor suppressor (dlg)/
tight junction protein (ZO1)
PKC: Protein kinase C
PMA: Phorbol 12-myristate 13-acetate
RCT: Reverse cholesterol transport
SR-BI: Scavenger receptor, class B, type I.
Acknowledgments
Flow cytometry and ﬂuorescence-activated cell sorting was
performed by Nicole McFarlane in the McMaster University
Biophotonics Facility. This paper was funded by Grants to
BLT from the Canadian Institutes of Health Research (MOP
74753) and the Heart and Stroke Foundation of Ontario
(NA6310). The Atherothrombosis Research Group is funded
by a Program Grant from the Heart and Stroke Foundation
of Ontario (PRG6502). Rachelle Brunet was the recipient
of a Heart and Stroke Foundation of Ontario graduate
scholarship.
References
[ 1 ] S .A c t o n ,A .R i g o t t i ,K .T .L a n d s c h u l z ,S .X u ,H .H .H o b b s ,a n d
M. Kriegert, “Identiﬁcation of scavenger receptor SR-BI as a
high density lipoprotein receptor,” Science, vol. 271, no. 5248,
pp. 518–520, 1996.
[2] C. Glass, R. C. Pittman, D. B. Weinstein, and D. Steinberg,
“Dissociation of tissue uptake of cholesterol ester from that of
apoproteinA-Iofratplasmahighdensitylipoprotein:selective
delivery of cholesterol ester to liver, adrenal, and gonad,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 80, no. 17, pp. 5435–5439, 1983.
[ 3 ]J .A .G l o m s e t ,“ H i g h - d e n s i t yl i p o p r o t e i n si nh u m a nh e a l t h
and disease,” Advances in Internal Medicine, vol. 25, pp. 91–
116, 1980.
[4] M. Krieger, “Charting the fate of the ’good cholesterol’: iden-
tiﬁcation and characterization of the high-density lipoprotein
receptor SR-BI,” Annual Review of Biochemistry, vol. 68, pp.
523–558, 1999.
[ 5 ] A .R i g o t t i ,B .L .T r i g a t t i ,M .P e n m a n ,H .R a y b u r n ,J .H e r z ,a n d
M. Krieger, “A targeted mutation in the murine gene encoding
the high density lipoprotein (HDL) receptor scavenger recep-
tor class B type I reveals its key role in HDL metabolism,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 94, no. 23, pp. 12610–12615, 1997.
[6] B. Trigatti, H. Rayburn, M. Vi˜ nals et al., “Inﬂuence of the
high density lipoprotein receptor SR-BI on reproductive and
cardiovascular pathophysiology,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 96, no.
16, pp. 9322–9327, 1999.
[7] P. Mardones, V. Qui˜ nones, L. Amigo et al., “Hepatic choles-
terol and bile acid metabolism and intestinal cholesterol
absorptioninscavengerreceptorclassBtypeI-deﬁcientmice,”
Journal of Lipid Research, vol. 42, no. 2, pp. 170–180, 2001.
[8] S. Zhang, M. H. Picard, E. Vasile et al., “Diet-induced occlu-
sive coronary atherosclerosis, myocardial infarction, cardiac
dysfunction, and premature death in scavenger receptor class
B type I-deﬁcient, hypomorphic apolipoprotein ER61 mice,”
Circulation, vol. 111, no. 25, pp. 3457–3464, 2005.
[9] M.L.Varban,F.Rinninger,N.Wangetal.,“Targetedmutation
reveals a central role for SR-BI in hepatic selective uptake
of high density lipoprotein cholesterol,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 95, no. 8, pp. 4619–4624, 1998.
[10] R. Out, M. Hoekstra, J. A. A. Spijkers et al., “Scavenger
receptor class B type I is solely responsible for the selective
uptake of cholesteryl esters from HDL by the liver and the
adrenals in mice,” Journal of Lipid Research, vol. 45, no. 11, pp.
2088–2095, 2004.
[11] M. Brundert, A. Ewert, J. Heeren et al., “Scavenger receptor
class B type I mediates the selective uptake of high-density
lipoprotein-associated cholesteryl ester by the liver in mice,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no.
1, pp. 143–148, 2005.
[12] K. F. Kozarsky, M. H. Donahee, A. Rigotti, S. N. Iqbal, E.
R. Edelman, and M. Krieger, “Overexpression of the HDL
receptor SR-BI alters plasma HDL and bile cholesterol levels,”
Nature, vol. 387, no. 6631, pp. 414–417, 1997.
[13] N. Wang, T. Arai, Y. Ji, F. Rinninger, and A. R. Tall, “Liver-
speciﬁc overexpression of scavenger receptor BI decreases
levels of very low density lipoprotein ApoB, low density
lipoprotein ApoB, and high density lipoprotein in transgenic
mice,” Journal of Biological Chemistry, vol. 273, no. 49, pp.
32920–32926, 1998.
[14] Y. Ueda, L. Royer, E. Gong et al., “Lower plasma levels and
accelerated clearance of high density lipoprotein (HDL) and
non-HDL cholesterol in scavenger receptor class B type I
transgenic mice,” Journal of Biological Chemistry, vol. 274, no.
11, pp. 7165–7171, 1999.
[15] T. Gordon, W. P. Castelli, M. C. Hjortland, W. B. Kannel,
and T. R. Dawber, “High density lipoprotein as a protective
factoragainstcoronaryheartdisease.TheFraminghamstudy,”
AmericanJournalofMedicine,vol.62,no.5,pp.707–714,1977.
[16] A. Braun, B. L. Trigatti, M. J. Post et al., “Loss of SR-BI10 Cholesterol
expression leads to the early onset of occlusive atheroscle-
rotic coronary artery disease, spontaneous myocardial infarc-
tions, severe cardiac dysfunction, and premature death in
apolipoproteinE-deﬁcientmice,”CirculationResearch,vol.90,
no. 3, pp. 270–276, 2002.
[ 1 7 ]K .F .K o z a r s k y ,M .H .D o n a h e e ,J .M .G l i c k ,M .K r i e g e r ,a n d
D. J. Rader, “Gene transfer and hepatic overexpression of the
HDLreceptorSR-BIreducesatherosclerosisinthecholesterol-
fed LDL receptor-deﬁcient mouse,” Arteriosclerosis, Thrombo-
sis, and Vascular Biology, vol. 20, no. 3, pp. 721–727, 2000.
[18] T. Arai, N. Wang, M. Bezouevski, C. Welch, and A. R.
Tall, “Decreased atherosclerosis in heterozygous low density
lipoprotein receptor-deﬁcient mice expressing the scavenger
receptor BI transgene,” Journal of Biological Chemistry, vol.
274, no. 4, pp. 2366–2371, 1999.
[ 1 9 ]Y .U e d a ,E .G o n g ,L .R o y e r ,P .N .C o o p e r ,O .L .F r a n c o n e ,
and E. M. Rubin, “Relationship between expression levels and
atherogenesisinscavengerreceptorclassB,typeItransgenics,”
Journal of Biological Chemistry, vol. 275, no. 27, pp. 20368–
20373, 2000.
[20] Y. Zhang, J. R. Da Silva, M. Reiliy, J. T. Billheimer, G. H.
Rothblat, and D. J. Rader, “Hepatic expression of scavenger
receptor class B type I (SR-BI) is a positive regulator of
macrophage reverse cholesterol transport in vivo,” Journal of
Clinical Investigation, vol. 115, no. 10, pp. 2870–2874, 2005.
[21] M. Ikemoto, H. Arai, D. Feng et al., “Identiﬁcation of a PDZ-
domain-containing protein that interacts with the scavenger
receptor class B type I,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 97, no. 12, pp.
6538–6543, 2000.
[22] D. L. Silver, “A carboxyl-terminal PDZ-interacting domain
of scavenger receptor B, type I is essential for cell surface
expression in liver,” Journal of Biological Chemistry, vol. 277,
no. 37, pp. 34042–34047, 2002.
[23] A. Yesilaltay, O. Kocher, R. Pal et al., “PDZK1 is required for
maintaining hepatic scavenger receptor, class B, type I (SR-BI)
steady state levels but not its surface localization or function,”
Journal of Biological Chemistry, vol. 281, no. 39, pp. 28975–
28980, 2006.
[24] Y. Nakagawa-Toyama, K. I. Hirano, K. I. Tsujii et al., “Human
scavenger receptor class B type I is expressed with cell-speciﬁc
fashion in both initial and terminal site of reverse cholesterol
transport,” Atherosclerosis, vol. 183, no. 1, pp. 75–83, 2005.
[25] O. Kocher, A. Yesilaltay, C. Cirovic, R. Pal, A. Rigotti, and
M. Krieger, “Targeted disruption of the PDZK1 gene in mice
causes tissue-speciﬁc depletion of the high density lipoprotein
receptor scavenger receptor class B type I and altered lipopro-
tein metabolism,” Journal of Biological Chemistry, vol. 278, no.
52, pp. 52820–52825, 2003.
[26] T. Kimura, H. Tomura, C. Mogi et al., “Role of scavenger
receptor class B type I and sphingosine 1-phosphate receptors
in high density lipoprotein-induced inhibition of adhesion
molecule expression in endothelial cells,” Journal of Biological
Chemistry, vol. 281, no. 49, pp. 37457–37467, 2006.
[27] Y. Zhang, A. M. Ahmed, N. McFarlane et al., “Regulation
of SR-BI-mediated selective lipid uptake in Chinese hamster
ovary-derived cells by protein kinase signaling pathways,”
Journal of Lipid Research, vol. 48, no. 2, pp. 405–416, 2007.
[28] Y. Zhang, A. M. Ahmed, T. L. Tran et al., “The inhibition
of endocytosis aﬀects HDL-lipid uptake mediated by the
humanscavengerreceptorclassBtypeI,”MolecularMembrane
Biology, vol. 24, no. 5-6, pp. 442–454, 2007.
[29] M. J. Chapman, S. Goldstein, D. Lagrange, and P. M. Laplaud,
“Adensitygradientultracentrifugalprocedurefortheisolation
of the major lipoprotein classes from human serum,” Journal
of Lipid Research, vol. 22, no. 2, pp. 339–358, 1981.
[30] G. D. Reynolds and R. W. St. Clair, “A comparative micro-
scopic and biochemical study of the uptake of ﬂuorescent and
I-labeled lipoproteins by skin ﬁbroblasts, smooth muscle cells,
and peritoneal macrophages in culture,” American Journal of
Pathology, vol. 121, no. 2, pp. 200–211, 1985.
[31] J. Babitt, B. Trigatti, A. Rigotti et al., “Murine SR-BI, a
high density lipoprotein receptor that mediates selective lipid
uptake, is N-glycosylated and fatty acylated and colocalizes
with plasma membrane caveolae,” Journal of Biological Chem-
istry, vol. 272, no. 20, pp. 13242–13249, 1997.
[32] T. J. F. Nieland, M. Penman, L. Dori, M. Krieger, and T.
Kirchhausen,“Discoveryofchemicalinhibitorsoftheselective
transfer of lipids mediated by the HDL receptor SR-BI,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 24, pp. 15422–15427, 2002.
[33] T. J. F. Nieland, M. Penman, L. Dori, M. Krieger, and T.
Kirchhausen,“Discoveryofchemicalinhibitorsoftheselective
transfer of lipids mediated by the HDL receptor SR-BI,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 24, pp. 15422–15427, 2002.
[34] D. L. Silver, N. Wang, X. Xiao, and A. R. Tall, “High density
lipoprotein (HDL) particle uptake mediated by scavenger
receptor class B type 1 results in selective sorting of HDL
cholesterol from protein and polarized cholesterol secretion,”
Journal of Biological Chemistry, vol. 276, no. 27, pp. 25287–
25293, 2001.
[35] A. L. Tondu, C. Robichon, L. Yvan-Charvet et al., “Insulin and
angiotensin II induce the translocation of scavenger receptor
class B, type I from intracellular sites to the plasma membrane
ofadipocytes,” JournalofBiologicalChemistry,vol.280,no.39,
pp. 33536–33540, 2005.
[36] C. J. Harder, A. Meng, P. Rippstein, H. M. McBride, and R.
McPherson,“SR-BIundergoescholesterol-stimulatedtranscy-
tosis to the bile canaliculus in polarized WIF-B cells,” Journal
of Biological Chemistry, vol. 282, no. 2, pp. 1445–1455, 2007.
[ 3 7 ]P .V .B u r g o s ,C .K l a t t e n h o ﬀ, E. de la Fuente, A. Rigotti, and
A. Gonz´ alez, “Cholesterol depletion induces PKA-mediated
basolateral-to-apical transcytosis of the scavenger receptor
class B type I in MDCK cells,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 101,
no. 11, pp. 3845–3850, 2004.
[38] T. A. Pagler, S. Rhode, A. Neuhofer et al., “SR-BI-mediated
high density lipoprotein (HDL) endocytosis leads to HDL
resecretion facilitating cholesterol eﬄux,” Journal of Biological
Chemistry, vol. 281, no. 16, pp. 11193–11204, 2006.
[39] S.Shetty,E.R.M.Eckhardt,S.R.Post,andD.R.vanderWest-
huyzen, “Phosphatidylinositol-3-kinase regulates scavenger
receptor Class B type I subcellular localization and selective
lipid uptake in hepatocytes,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 26, no. 9, pp. 2125–2131, 2006.
[40] T. J. F. Nieland, M. Ehrlich, M. Krieger, and T. Kirchhausen,
“Endocytosis is not required for the selective lipid uptake
mediatedbymurineSR-BI,”BiochimicaetBiophysicaActa,vol.
1734, no. 1, pp. 44–51, 2005.
[41] W.M.Cao,K.Murao,H.Imachietal.,“Amutanthigh-density
lipoprotein receptor inhibits proliferation of human breast
cancer cells,” Cancer Research, vol. 64, no. 4, pp. 1515–1521,
2004.
[42] D. Masson, M. Koseki, M. Ishibashi et al., “Increased HDL
cholesterol and ApoA-I in humans and mice treated with
a novel SR-BI inhibitor,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 29, no. 12, pp. 2054–2060, 2009.Cholesterol 11
[ 4 3 ]L .M .T o r r e s ,C .C e f a r a t t i ,B .P e r r y ,a n dA .R o m a n i ,“ I n v o l v e -
ment of ERK1/2 and p38 in Mg accumulation in liver cells,”
MolecularandCellularBiochemistry,vol.288,no.1-2,pp.191–
199, 2006.
[44] R. Carini, M. Grazia de Cesaris, R. Splendore et al., “Signal
pathway involved in the development of hypoxic precondi-
tioning in rat hepatocytes,” Hepatology, vol. 33, no. 1, pp. 131–
139, 2001.
[45] S. Takai, R. Matsushima-Nishiwaki, H. Tokuda et al., “Protein
kinaseCδ regulatesthephosphorylationofheatshockprotein
27 in human hepatocellular carcinoma,” Life Sciences, vol. 81,
no. 7, pp. 585–591, 2007.
[46] K. Guo, Y. Liu, H. Zhou et al., “Involvement of protein
kinaseCβ-extracellularsignal-regulatingkinase/p38mitogen-
activated protein kinase-heat shock protein 27 activation in
hepatocellular carcinoma cell motility and invasion,” Cancer
Science, vol. 29, no. 3, pp. 486–496, 2008.
[47] G.Baldanzi,E.Alchera,C.Imarisioetal.,“Negativeregulation
of diacylglycerol kinase mediates adenosine-dependent hep-
atocyte preconditioning,” Cell Death and Diﬀerentiation, vol.
17, no. 6, pp. 1059–1068, 2010.